Published in Antimicrob Agents Chemother on March 01, 2004
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother (2005) 1.08
Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother (2009) 1.05
Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob Agents Chemother (2009) 1.01
Comparison of echinocandin antifungals. Ther Clin Risk Manag (2007) 0.99
Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob Agents Chemother (2014) 0.98
Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob Agents Chemother (2007) 0.90
Yeast colonization and drug susceptibility pattern in the pediatric patients with neutropenia. Jundishapur J Microbiol (2014) 0.85
The Aspergillus fumigatus cell wall integrity signaling pathway: drug target, compensatory pathways, and virulence. Front Microbiol (2015) 0.85
Efficacy of Amphotericin B at Suboptimal Dose Combined with Voriconazole in a Murine Model of Aspergillus fumigatus Infection with Poor In Vivo Response to the Azole. Antimicrob Agents Chemother (2013) 0.81
Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata. Antimicrob Agents Chemother (2009) 0.80
Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2012) 0.79
Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species. Mycopathologia (2013) 0.79
Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions. Antimicrob Agents Chemother (2013) 0.79
In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp. Antimicrob Agents Chemother (2012) 0.76
In Vitro and In Vivo Efficacy of Amphotericin B Combined with Posaconazole against Experimental Disseminated Sporotrichosis. Antimicrob Agents Chemother (2015) 0.75
In Vitro Triple Combination of Antifungal Drugs against Clinical Scopulariopsis and Microascus Species. Antimicrob Agents Chemother (2015) 0.75
In vitro evaluation of antifungal drug combinations against Sarocladium (Acremonium) kiliense, an opportunistic emergent fungus resistant to antifungal therapies. Antimicrob Agents Chemother (2013) 0.75
Successful management of Aspergillus liver abscess in a patient with necrotizing fasciitis. Dig Dis Sci (2007) 0.75
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Invasive aspergillosis. Clin Infect Dis (1998) 9.72
A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52
Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis (2001) 6.32
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis (2002) 6.13
Current and emerging azole antifungal agents. Clin Microbiol Rev (1999) 5.70
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 4.75
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother (2001) 3.28
Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother (2000) 3.08
Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother (1996) 3.03
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother (2002) 2.76
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis (2003) 2.73
Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother (2001) 2.69
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother (2002) 2.68
Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis (1998) 2.40
Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother (2003) 2.27
Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother (2002) 2.26
Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol (2003) 1.89
In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother (2003) 1.85
Tuberculosis in the AIDS era. Clin Microbiol Rev (1995) 1.85
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother (1995) 1.77
In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2002) 1.65
Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother (2000) 1.50
Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother (1999) 1.48
Caspofungin. Drugs (2001) 1.45
Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1996) 1.41
Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy (1987) 1.40
Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother (2003) 1.36
Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine. Antimicrob Agents Chemother (1977) 1.32
Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob Agents Chemother (1997) 1.23
The past, present and future of antimycotic combination therapy. Mycoses (1999) 1.18
In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob Agents Chemother (2003) 1.17
Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol (2000) 1.17
Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer (2003) 1.02
In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother (2003) 1.01
Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother (2003) 1.00
Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter. Antimicrob Agents Chemother (2003) 0.97
The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media. J Antimicrob Chemother (1998) 0.91
Use of spectrophotometric reading for in vitro antifungal susceptibility testing of Aspergillus spp. Can J Microbiol (1999) 0.90
In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother (2002) 0.88
5-Fluorocytosine antagonizes the action of sterol biosynthesis inhibitors in Candida glabrata. J Antimicrob Chemother (1999) 0.87
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS (2005) 5.51
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med (2004) 4.47
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med (2008) 3.85
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med (2011) 3.63
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis (2010) 3.07
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med (2009) 3.07
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med (2007) 2.85
Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med (2012) 2.55
Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother (2008) 2.54
Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BMC Genomics (2008) 2.51
Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis (2009) 2.33
Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr (2007) 2.32
Cryptococcal cell morphology affects host cell interactions and pathogenicity. PLoS Pathog (2010) 2.28
Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis (2002) 2.20
Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS (2006) 2.19
Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun (2008) 2.15
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS (2004) 2.11
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood (2006) 2.06
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother (2010) 2.02
Molecular identification of zygomycetes from culture and experimentally infected tissues. J Clin Microbiol (2006) 1.96
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol (2005) 1.80
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78
Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol (2011) 1.76
Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol (2002) 1.76
Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis (2003) 1.74
Idiopathic CD4+ T-cell lymphocytopenia is associated with impaired membrane expression of the chemokine receptor CXCR4. Blood (2009) 1.74
Literature review and case histories of Histoplasma capsulatum var. duboisii infections in HIV-infected patients. Emerg Infect Dis (2007) 1.63
Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis (2009) 1.62
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60
Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J Clin Microbiol (2008) 1.57
β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis (2011) 1.56
Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res (2006) 1.54
Bacteremia in patients receiving TNF-alpha antagonists--a prospective multicenter study. J Infect (2013) 1.52
Cryptococcus neoformans Galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus Galactomannan. J Clin Microbiol (2005) 1.50
Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis (2012) 1.47
Human listeriosis caused by Listeria ivanovii. Emerg Infect Dis (2010) 1.46
Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med (2014) 1.45
Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans. Mol Microbiol (2002) 1.45
Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis (2012) 1.45
Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis (2008) 1.44
Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One (2008) 1.43
Healthcare-associated mucormycosis. Clin Infect Dis (2012) 1.42
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Molecular and phenotypic evaluation of Lichtheimia corymbifera (formerly Absidia corymbifera) complex isolates associated with human mucormycosis: rehabilitation of L. ramosa. J Clin Microbiol (2009) 1.36
Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.34
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother (2009) 1.34
Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) (2012) 1.31
AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid. Emerg Infect Dis (2008) 1.31
Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect Immun (2004) 1.31
Detection of caspofungin resistance in Candida spp. by Etest. J Clin Microbiol (2008) 1.29
Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am (2010) 1.29
Molecular identification of black-grain mycetoma agents. J Clin Microbiol (2006) 1.28
Complete glycosylphosphatidylinositol anchors are required in Candida albicans for full morphogenesis, virulence and resistance to macrophages. Mol Microbiol (2002) 1.28
Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect Immun (2003) 1.27
Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis (2014) 1.25
Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis. J Clin Microbiol (2011) 1.24
Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene (2003) 1.23
Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol (2012) 1.23
[Chikungunya virus: a reemerging alphavirus]. Med Sci (Paris) (2006) 1.22
Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS (2006) 1.22
Mixed infections and In Vivo evolution in the human fungal pathogen Cryptococcus neoformans. MBio (2010) 1.21
Deletions of endocytic components VPS28 and VPS32 affect growth at alkaline pH and virulence through both RIM101-dependent and RIM101-independent pathways in Candida albicans. Infect Immun (2005) 1.19
Addressing the challenge of extended-spectrum beta-lactamases. Curr Opin Investig Drugs (2009) 1.17
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother (2013) 1.16
Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis (2005) 1.15
Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One (2010) 1.15
The Yak1p kinase controls expression of adhesins and biofilm formation in Candida glabrata in a Sir4p-dependent pathway. Mol Microbiol (2005) 1.14
Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One (2008) 1.14
An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis (2005) 1.14
Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis (2011) 1.13
Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother (2006) 1.13
Herpes esophagitis: a comprehensive review. Clin Microbiol Infect (1997) 1.13
Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis (2008) 1.12
Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol (2005) 1.12